NSE · SYMBIOTEC

Symbiotec Pharmalab Limited

Sector: Healthcare · ISIN: INE899I01028

Historical price visualisation is temporarily undergoing corporate data-licensing maintenance. Full interactive price and chart data will return following our upcoming authorized NSE/BSE data-feed deployment. Derived metrics (valuation ratios, market-cap rank), company financials, shareholding, corporate actions, and mutual-fund holdings remain available.

Market cap rank

#657

of 5,049 stocks

🏆 New peak

▲ 141W

Peak #657 · 17 Oct 2026

Operating in Healthcare, Symbiotec Pharmalab Limited carries a steep earnings multiple that prices in strong future growth, draws sizeable foreign institutional interest (21% FII), and is growing revenue at a solid clip. Ownership as of Aug 2026.

Market Cap

8,026.94 Cr

P/E Ratio

74.82

P/B Ratio

7.15

ROE

9.56%

ROCE

14.26%

Dividend Yield

—

52W High

—

52W Low

—

Quarterly financials

Metric	Q1 2026-27	Q1 2025-26
Revenue	218.15 Cr	199.85 Cr
Net Profit	14.06 Cr	29.92 Cr
EPS	2.24	4.66
Operating Profit	23.71 Cr	47.85 Cr

Figures in Cr (crore) unless noted. Source: official company financial disclosures.

Shareholding pattern

Promoter

33.28%

Public

66.72%

PUBLIC BREAKDOWN

FII

21.08%

DII

27.52%

MF (within DII)

5.54%

Individuals

17.51%

As of 31 Aug 2026. FII, DII, MF & Individuals are sub-categories of Public.

Mutual fund holdings

₹931.72

Cr total

Schemes

Fund Houses

₹931.72 Cr

Total Exposure

Mirae Asset Mutual Fund₹477.03 Cr (51.2%)

Motilal Oswal Mutual Fund₹109.33 Cr (11.7%)

ICICI Prudential Mutual Fund₹104.41 Cr (11.2%)

HDFC Mutual Fund₹53.60 Cr (5.8%)

Tata Mutual Fund₹31.08 Cr (3.3%)

Others₹156.27 Cr (16.8%)

Scheme	Fund House	Value (Cr)	%

All MF holders by market value as of 01 Sep 2026.

Recent corporate actions

No corporate actions on record for this stock.

Need this data in your app?

Full price history, technical indicators, and every field above via one REST API call.

View API docs